JPMorgan raised the firm’s price target on GSK (GSK) to 1,500 GBp from 1,440 GBp and keeps an Underweight rating on the shares. Published first on TheFly – the ultimate source for real-time ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed yesterday at p1,485. ...

Glaxo Wellcome agreed to pay the University royalties on the worldwide sale of Ziagen, an AIDS-inhibiting drug, University President Mark Yudof announced Tuesday. About two-thirds of the royalty ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

Teva Pharmaceutical Industries Ltd. ADR-2.66% $19.77B ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth? The content of this article is ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...